Crossmark

Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s00261-021-03248-9

Published Online: 2021-08-19

Published Print: 2021-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hai, Yang

Savsani, Esika

Chong, Weelic

Eisenbrey, John

Lyshchik, Andrej https://orcid.org/0000-0001-8930-2213
Funding

Funding for this research was provided by:

National Institutes of Health (CA215520)

National Institutes of Health (CA238241)

National Institutes of Health (CA194307)
License Information

Text and Data Mining valid from 2021-08-19

Version of Record valid from 2021-08-19
More Information

Article History

Received: 1 June 2021

Revised: 9 August 2021

Accepted: 10 August 2021

First Online: 19 August 2021

Declarations

:

: Yang Hai, Esika Savsani, and Weelic Chong have no relevant financial or non-financial interests to disclose. John Eisenbrey: GE Healthcare: grants and equipment support. Lantheus Medical Imaging: drug support and speaker fees. Siemens: equipment support. Book Royalties: Elsevier. Andrej Lyshchik: Research support: GE Healthcare, Bracco Diagnostics, Siemens Healthineers, Canon Medical Systems. Advisory Board: Bracco Diagnostics. Consulting: GE Healthcare, Bioclinica, WorldCare Clinical. Speaker Panel: GE Healthcare. Book Royalties: Elsevier.

: This is a meta-analysis of already published data and no ethical approval or incorment consent is required for this study.

Document is current

Any future updates will be listed below